11/03/2015 : THERADIAG strengthens its positioning in the oncology theranostics market with its Herceptin® monitoring test receiving CE marking

Croissy-Beaubourg and Montpellier, March 11, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today it has received CE marking for the Herceptin® (trastuzumab) monitoring test that expend…

Continue Reading 11/03/2015 : THERADIAG strengthens its positioning in the oncology theranostics market with its Herceptin® monitoring test receiving CE marking

04/03/2015 : FULL YEAR RESULTS 2014

Sales revenues up by 6%, led by sales of proprietary products 3rd consecutive year of increase in theranostics sales : x 3.6 Improvement in gross profit margin : + 5 points Strengthening of R&D developments…

Continue Reading 04/03/2015 : FULL YEAR RESULTS 2014

03/02/2015 : THERADIAG and UCB enter into a master services agreement

Croissy-Beaubourg and Montpellier, February 3, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces today that it has entered into a master services agreement with the biopharmaceutical…

Continue Reading 03/02/2015 : THERADIAG and UCB enter into a master services agreement